DexCom Stock Plunge Raises Big Questions – Will This Diabetes Tech Leader Rebound?
DexCom shares plunged nearly 17% to a 52-week low near $56 on Oct. 31 after management warned 2026 growth may lag Wall Street targets. Q3 revenue rose 22% to $1.21 billion, beating estimates, but profit margins missed some forecasts. The stock is down 27% year-to-date. Several analysts cut price targets, though most still rate the stock a “Strong Buy.”